Checkpoint Therapeutics, INC 8-K filings

Checkpoint Therapeutics, Inc. has finalized its merger with Sun Pharmaceutical Industries, Inc., becoming a wholly-owned subsidiary and delisting from Nasdaq, with shareholders receiving $4.10 cash per share plus a contingent value right.

Checkpoint Therapeutics, Inc. stockholders have overwhelmingly approved the Agreement and Plan of Merger with Sun Pharmaceutical Industries, Inc., moving the company closer to becoming a wholly-owned subsidiary of Sun Pharma.

Checkpoint Therapeutics and Sun Pharma's merger progresses as the Hart-Scott-Rodino waiting period expires, with the deal expected to close around May 30, 2025, pending stockholder approval and other customary conditions.

Checkpoint Therapeutics reported its Q1 2025 financial results, highlighted by FDA approval of UNLOXCYT and an upcoming stockholder vote on a merger with Sun Pharmaceutical Industries.

Checkpoint Therapeutics and Sun Pharmaceutical Industries amend their merger agreement, modifying the definition of 'Company Required Vote' to include both a majority of unaffiliated stockholders and a majority of outstanding common stock.

Checkpoint Therapeutics reports its full-year 2024 financial results, highlighted by the FDA approval of UNLOXCYT and a pending merger agreement with Sun Pharmaceutical Industries.

Sun Pharma will acquire Checkpoint Therapeutics, adding the FDA-approved UNLOXCYT (cosibelimab-ipdl) for advanced cutaneous squamous cell carcinoma (cSCC) to its oncology portfolio.

Checkpoint Therapeutics formalizes employment terms with CFO Garrett Gray, outlining compensation, bonus potential, and severance benefits.

Checkpoint Therapeutics has announced FDA approval for UNLOXCYT (cosibelimab-ipdl), a first-of-its-kind anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma.

Checkpoint Therapeutics reported its Q3 2024 financial results, highlighted by a strengthened cash position and progress on its cosibelimab Biologics License Application (BLA).

Checkpoint Therapeutics reported its second quarter 2024 financial results, provided a corporate update, and announced the resubmission of its Biologics License Application (BLA) for cosibelimab.

Checkpoint Therapeutics has announced that the FDA has accepted the resubmission of its Biologics License Application (BLA) for cosibelimab, a potential treatment for advanced cutaneous squamous cell carcinoma, with a PDUFA goal date set for December 28, 2024.

Checkpoint Therapeutics has finalized a $12 million direct offering and resubmitted its biologics license application for cosibelimab to the FDA.

Checkpoint Therapeutics has reached an agreement with the FDA on its strategy to resubmit its biologics license application for cosibelimab, a potential treatment for advanced skin cancer.

Checkpoint Therapeutics' stockholders approved an increase in authorized shares and an expansion of the company's incentive plan at the 2024 annual meeting.

Checkpoint Therapeutics announced its first quarter 2024 financial results and provided an update on its plans to resubmit the Biologics License Application (BLA) for cosibelimab.

Checkpoint Therapeutics reported its 2023 financial results, highlighted by a decrease in net loss and progress towards resubmitting its Biologics License Application (BLA) for cosibelimab.

Checkpoint Therapeutics has appointed Dr. Amit Sharma to its Board of Directors, resolving a Nasdaq listing deficiency and adding significant industry expertise.

Checkpoint Therapeutics has received a notice from Nasdaq for not meeting board independence requirements following a director's resignation, but has until January 2025 to regain compliance.

Checkpoint Therapeutics has entered into a definitive agreement for a $14 million registered direct offering with a healthcare-dedicated institutional investor.